109 research outputs found
Acute superior mesenteric venous thrombosis with advanced gastric cancer: a case report
Although the advanced stages of neoplasms have a risk of superior mesenteric venous thrombosis (MVT), an initial clinical diagnosis of MVT is sometimes difficult and it can be treated as a cancer-related pain using NSAIDs and/or opioids
Brain uptake and safety of Flutemetamol F 18 injection in Japanese subjects with probable Alzheimer’s disease, subjects with amnestic mild cognitive impairment and healthy volunteers
Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: synopsis of Version 2.0
Ethnic comparison of pharmacokinetics of 18F-florbetaben, a PET tracer for beta-amyloid imaging, in healthy Caucasian and Japanese subjects
The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006–2009) nationwide survey
Investigation of the factors associated with circulating soluble CD36 levels in patients with HCV-related chronic liver disease
Detection of prostate cancer by an FDG-PET cancer screening program: results from a Japanese nationwide survey
Objective(s): The aim of this study was to analyze detection rates and effectiveness of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) cancer screening program for prostate cancer in Japan, which is defined as a cancer-screening program for subjects without known cancer. It contains FDG-PET aimed at detection of cancer at an early stage with or without additional screening tests such as prostate-specific antigen (PSA) and magnetic resonance imaging (MRI).
Methods: A total of 92,255 asymptomatic men underwent the FDG-PET cancer screening program. Of these, 504 cases with findings of possible prostate cancer in any screening method were analyzed.
Results: Of the 504 cases, 165 were verified as having prostate cancer. Of these, only 61 cases were detected by FDG-PET, which result in 37.0% relative sensitivity and 32.8% positive predictive value (PPV). The sensitivity of PET/computed tomography (CT) scanner was higher than that of dedicated PET (44.0% vs. 20.4%). However, the sensitivity of FDGPET was lower than that of PSA and pelvic MRI. FDG-PET did not contribute to improving the sensitivity and PPV when performed as combined screening.
Conclusion: PSA should be included in FDG-PET cancer screening programs to screen for prostate cancer
Visualization of Correlated Hemodynamic and Metabolic Functions in Cerebrovascular Disease by a Cluster Analysis with PET Study
- …